Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aim...

Full description

Bibliographic Details
Main Authors: Thomas Urup, Linn Gillberg, Katja Kaastrup, Maya Jeje Schuang Lü, Signe Regner Michaelsen, Vibeke Andrée Larsen, Ib Jarle Christensen, Helle Broholm, Ulrik Lassen, Kirsten Grønbæk, Hans Skovgaard Poulsen
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Molecular Oncology
Subjects:
bevacizumab
DNA methylation
glioblastoma
local renin–angiotensin system
predictive biomarker
Online Access:https://doi.org/10.1002/1878-0261.12660

Internet

https://doi.org/10.1002/1878-0261.12660

Similar Items